Pharmaceutical composition comprising acetylsalicylic acid and proton pump inhibitor

By separating acetylsalicylic acid and proton pump inhibitor into independent units and using enteric coating and moisture-proof inner coating technology, the problems of uneven stability and release of pharmaceutical compositions are solved, achieving better efficacy and Side effects control.

CN119072315APending Publication Date: 2024-12-03HANMI PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202380034892.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-07-19
Filing Date
2023-01-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the existing pharmaceutical compositions, acetylsalicylic acid and proton pump inhibitors are reduced in stability and unevenly released due to interaction, and cannot be released independently, which affects the efficacy.

Method used

Separate acetylsalicylic acid and proton pump inhibitor into separate units and physically separate them in granules, pills or tablets respectively. Ensure independent release of each component through enteric coating and moisture-proof inner coating technology to prevent interactions .

Benefits of technology

Improves the stability and dissolution rate of the pharmaceutical composition, ensures the optimal efficacy of each ingredient, and reduces side effects, especially acid resistance and release efficiency in the gastrointestinal environment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072315A_ABST
    Figure CN119072315A_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising: a first unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical composition according to the present invention is divided into a first unit and a second unit, thereby preventing direct contact between drugs. Thus, stability is achieved and the effect on the individual release of the corresponding drug is minimized, thereby exhibiting improved elution.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical composition comprising a first unit and a second unit, wherein the first unit comprises acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and the second unit comprises a proton pump inhibitor, and the pharmaceutical composition exhibits improved stability and dissolution rate. Background Art

[0002] Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to cause side effects, including gastric bleeding and kidney damage. In the U.S., there are more than 13 million NSAID regular users, 70 million NSAID prescriptions are issued each year, and 30 billion over-the-counter NSAID tablets are sold each year. NSAID-induced diseases lead to 130,000 days of hospitalization each year, and an estimated 16,500 deaths are expected each year. Twenty percent of all NSAID users will suffer from peptic ulcers, and NSAID users have a significant risk of upper gastrointestinal bleeding, which is three to four times higher. In addition, people over the age of 60 are significantly more likely to suffer from complications associated with oral NSAIDs.

[0003] Among these NSAIDs, acetylsalicylic acid is used as an anti-inflammatory agent, as well as for inhibiting thrombosis in myocardial infarction, cerebral infarction, or unstable angina, for inhibiting thrombosis after coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, or for reducing cardiovascular risk in high-risk patients (those with combined risk factors such as a family history of ischemic heart disease, hypertension, hypercholesterolemia, obesity, and diabetes). When used to inhibit thrombosis or reduce cardiovascular risk, the side effects of acetylsalicylic acid (such as gastrointestinal ulcers and bleeding) are more severe because it is usually taken for a much longer period of time than when used as an anti-inflammatory agent.

[0004] Meanwhile, proton pump inhibitors (eg, rabeprazole, omeprazole, etc.) are widely used as the treatment of peptic ulcers due to their effective inhibition of gastric acid secretion and protection of gastric mucosa.

[0005] The concomitant use of NSAIDs containing acetylsalicylic acid with proton pump inhibitors has been studied to control the gastrointestinal side effects of NSAIDs, and national and international guidelines recommend the combination of acetylsalicylic acid and proton pump inhibitors based on large clinical trials.

[0006] Korean registered patent No. 10-1952478 discloses a dry-coated tablet containing acetylsalicylic acid in the inner core and a proton pump inhibitor in the outer layer, but the problem is that the two drugs are located in the inner layer and the outer layer, respectively, which may lead to reduced content stability due to potential interactions between the drugs. In addition, the drugs cannot be released independently and may affect each other.

[0007] In addition, Korean Patent No. 10-1908748 discloses an orally disintegrating tablet comprising an enteric fine granule layer and an acetylsalicylic acid-containing layer, the enteric fine granule layer containing a proton pump inhibitor. However, since the two drugs are stacked, there is a concern that the content stability may be reduced due to interaction. Summary of the invention

[0008]

Technical issues

[0009] The present invention aims to provide a pharmaceutical composition comprising a first unit and a second unit, wherein the first unit comprises acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and the second unit comprises a proton pump inhibitor, wherein the pharmaceutical composition exhibits improved stability and dissolution rate.

[0010]

Technical solution

[0011] The present invention provides a pharmaceutical composition comprising: a first unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor.

[0012] The first unit of the present invention may contain acetylsalicylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

[0013] Acetylsalicylic acid is one of the NSAIDs, has antipyretic, analgesic and anti-inflammatory properties, and is widely used in pharmaceutical products, such as aspirin for antipyretic, analgesic and anti-inflammatory purposes, or Aspirin Protect Tablet for antithrombotic or platelet aggregation inhibition purposes, depending on the dosage and indication.

[0014] Acetylsalicylic acid or a pharmaceutically acceptable salt thereof according to the present invention may have a dosage of 50 to 150 mg per unit dosage form.

[0015] Preferably, acetylsalicylic acid or a pharmaceutically acceptable salt thereof according to the present invention may have a dosage of 50 to 100 mg per unit dosage form.

[0016] The second unit of the present invention may contain a proton pump inhibitor as an active ingredient.

[0017] The proton pump inhibitor may be contained for the purpose of preventing and treating upper gastrointestinal bleeding and / or peptic ulcer, which are side effects that may occur when acetylsalicylic acid or a pharmaceutically acceptable salt thereof is administered, and may include any proton pump inhibitor known to be effective for upper gastrointestinal bleeding and / or peptic ulcer.

[0018] The proton pump inhibitor of the present invention can be selected from rabeprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, dexlansoprazole, ilaprazole, S-pantoprazole and pharmaceutically acceptable salts thereof.

[0019] Preferably, the proton pump inhibitor of the present invention may be rabeprazole or a pharmaceutically acceptable salt thereof.

[0020] The proton pump inhibitor may vary depending on the specific drug type, but the dosage per unit dosage form may be, for example, about 5 to 50 mg, or 5 to 20 mg.

[0021] Preferably, the proton pump inhibitor of the present invention may be rabeprazole or a pharmaceutically acceptable salt thereof, and the dosage thereof may be 5 to 20 mg per unit dosage form.

[0022] The first unit and the second unit of the present invention may each independently be any one or more selected from granules, pellets and tablets.

[0023] The proton pump inhibitor or a pharmaceutically acceptable salt thereof contained in the second unit of the present invention may be degraded by acetylsalicylic acid or a pharmaceutically acceptable salt thereof, which is an acidic component contained in the first unit, resulting in reduced content stability. In addition, the release of a composite composition containing two active ingredients like the present invention must be designed so that each ingredient can exert its optimal effect.

[0024] The pharmaceutical composition of the present invention may comprise a first unit and a second unit which are physically separated in the form of granules, pills or tablets, respectively, which prevents direct contact of active ingredients contained in each of the first unit and the second unit while ensuring independent release of these active ingredients.

[0025] Preferably, the first unit may be a pellet and the second unit may be a pellet.

[0026] Further, preferably, the first unit may be a pill, and the second unit may be a tablet.

[0027] Further, preferably, the first unit may be a tablet, and the second unit may be a pill.

[0028] Further, preferably, the first unit may be a tablet, and the second unit may be a tablet.

[0029] The pharmaceutical composition comprising the first unit and the second unit of the present invention may be in the form of a capsule or a tablet.

[0030] Tablets may be mixed tablets, bilayer tablets, multilayer tablets, matrix tablets, core tablets or coated tablets, and capsules may be poly-caps, coated capsules or the like.

[0031] Preferably, the pharmaceutical composition of the present invention is a capsule, and the capsule may contain a first unit and a second unit, and the first unit and the second unit are any one or more selected from granules, pills and tablets.

[0032] More preferably, the pharmaceutical composition of the present invention may be a poly-cap comprising a first unit in the form of granules, pills or tablets and a second unit in the form of granules, pills or tablets in one capsule.

[0033] In the present invention, poly-cap refers to a composite preparation in which two or more main ingredients are filled into one capsule in different, separate dosage forms. Specifically, poly-cap is a composite drug having a co-packaging concept in which two or more types of main ingredients are filled into one capsule, each ingredient being manufactured in the form of a pill, capsule, tablet, etc. These poly-caps contain several types of main ingredients, each of which has the same dissolution rate and pharmacokinetics (PK) as a single dosage form, and since the ingredients in the capsule are separated, they have the advantage of excellent stability by minimizing interactions.

[0034] Figure 1 The structure of the poly-cap of the present invention is shown, wherein enteric-coated pellets containing acetylsalicylic acid (shown as enteric-coated aspirin pellets) and enteric-coated tablets containing rabeprazole (shown as enteric-coated Rabe tablets) are contained in one capsule as the first unit and the second unit, respectively.

[0035] Figure 2 An image showing a poly-cap produced in Example 3 of the present invention, in which small white pills (first unit) and yellow tablets (second unit) are contained in one capsule.

[0036] As described above, the pharmaceutical composition according to the present invention exhibits excellent stability and dissolution rate because two drugs are respectively present in the first unit and the second unit, thereby preventing the interaction between the drugs contained in each unit.

[0037] The surface of the first unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof according to the present invention may be coated with an enteric coating base.

[0038] Furthermore, the surface of the second unit containing a proton pump inhibitor according to the present invention may be coated with an enteric coating base.

[0039] In consideration of the absorption site thereof, both the acetylsalicylic acid or a pharmaceutically acceptable salt thereof contained in the first unit and the proton pump inhibitor contained in the second unit are preferably controlled-release with an enteric base and released in the intestine.

[0040] Preferably, the surfaces of both the first unit and the second unit of the present invention may be coated with an enteric coating base.

[0041] Furthermore, if the proton pump inhibitor contained in the second unit is sensitive to moisture (eg, rabeprazole or a pharmaceutically acceptable salt thereof), it is preferred to form a moisture-proof inner coating layer on the surface of the second unit and then form an enteric coating layer thereon.

[0042] Preferably, the surface of the second unit of the present invention may be coated with a moisture-proof inner coating base, and further coated with an enteric coating base thereon.

[0043] Most preferably, the surface of the first unit of the present invention may be coated with an enteric coating base, and the surface of the second unit may be coated with a moisture-proof inner coating base, and further coated thereon with an enteric coating base.

[0044] The enteric coating base of the present invention can be any one or more selected from the following: hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate, shellac, methacrylic acid-ethyl acrylate copolymer (methacrylic acid-ethyl acrylate copolymer), ethyl acrylate-methyl methacrylate copolymer (ethyl acrylate-methyl methacrylate copolymer), acrylic acid, methacrylic acid, methacrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate trimellitate and sodium carboxymethyl cellulose.

[0045] Preferably, the enteric coating base of the present invention can be any one or more selected from the following: hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate, shellac, methacrylic acid-ethyl acrylate copolymer (methacrylic acid-ethyl acrylate copolymer) and ethyl acrylate-methyl methacrylate copolymer (ethyl acrylate-methyl methacrylate copolymer).

[0046] More preferably, the enteric coating base of the present invention may be hydroxypropylmethylcellulose phthalate.

[0047] Preferably, the content of the enteric coating may be 3 to 15% by weight relative to the second unit, wherein the second unit refers to uncoated granules, pellets or tablets (ordinary tablets).

[0048] When the content of the enteric coating is 3 to 15% by weight relative to the second unit, the drug contained in the second unit can suppress drug release in the stomach (acid resistance) and can be effectively released in the intestine, thereby ensuring drug content stability.

[0049] In a specific experimental example, dissolution tests were performed on Examples 1 to 4 and Comparative Examples 1 to 4 (which were produced by changing the enteric coating ratio). As a result, Comparative Examples 1 and 2 (wherein the enteric coating ratio was less than 3% by weight relative to rabeprazole ordinary tablets) showed a dissolution rate of 10% or more after 120 minutes in 0.1N HCl, indicating that acid resistance was not ensured. On the contrary, Comparative Examples 3 and 4 (wherein the enteric coating ratio exceeded 15% by weight relative to rabeprazole ordinary tablets) showed a dissolution rate of less than 85% after 45 minutes at pH 6.8, confirming insufficient drug release. At the same time, Examples 1 to 4 (wherein the enteric coating ratio was 3 to 15% by weight relative to rabeprazole ordinary tablets) showed both acid resistance and sufficient drug release ( Figure 3 and Figure 4 ).

[0050] Furthermore, in a specific experimental example, in Comparative Examples 1 and 2, the content of rabeprazole decreased to 95% or less at the 8th week of the accelerated test, and the rabeprazole RRT 0.80 related substances exceeded the reference value of 0.8% at the 8th week of the accelerated test, and the amount of the total rabeprazole related substances exceeded or approached the reference value of 2% at the 12th week of the accelerated test. On the other hand, Examples 1 and 4 (in which the enteric coating ratio was 3 to 15% by weight relative to the rabeprazole ordinary tablet) maintained 95% or more of the rabeprazole content during the 12-week accelerated test, and the amount of the rabeprazole RRT 0.80 related substances and the total amount of related substances were lower than the reference value, confirming good stability ( Figure 5 and Figure 7 ).

[0051] The moisture-proof inner coating base of the present invention may be any one or more selected from the group consisting of ethyl cellulose, Opadry OY-C-7000A, hydroxypropyl cellulose and hydroxypropyl methyl cellulose.

[0052] Preferably, the moisture-proof inner coating base of the present invention may be ethylcellulose.

[0053] Preferably, the content of the moisture-proof inner coating may be 1 to 3% by weight relative to the second unit, wherein the second unit refers to uncoated granules, pellets or tablets (ordinary tablets).

[0054] When the content of the moisture-proof inner coating is 1 to 3 wt % relative to the second unit, the best moisture-proof effect can be achieved for the moisture-sensitive drug contained in the second unit. When the content of the moisture-proof inner coating is less than 1 wt % relative to the second unit, it is not suitable because the low moisture-proof effect can reduce the stability of the drug contained in the second unit, and when it is more than 3 wt %, it is not suitable because it affects the release time of the drug.

[0055] Preferably, the second unit of the present invention may further comprise an alkaline stabilizer.

[0056] In addition, the moisture-proof inner coating of the present invention may further contain an alkaline stabilizer.

[0057] The alkaline stabilizer of the present invention may be any one or more selected from the group consisting of magnesium oxide, magnesium hydroxide, calcium hydroxide, sodium hydroxide, precipitated calcium carbonate and potassium hydroxide.

[0058] Preferably, the alkaline stabilizer of the present invention may be magnesium oxide.

[0059] Preferably, the bulk density of magnesium oxide may be less than 330 g / L.

[0060] Further, preferably, the bulk density of magnesium oxide may be greater than 0 and less than 330 g / L.

[0061] When the bulk density of the magnesium oxide included in the present invention is 330g / L or greater, a second unit (granule, pill or tablet) of higher density can be produced, which increases the strength of the second unit, thereby reducing the disintegration rate. Since magnesium oxide is insoluble in water, the disintegration rate of the second unit directly affects the drug release, and therefore, the reduction in the disintegration rate of the second unit also slows down the drug release. On the other hand, when the bulk density of magnesium oxide is less than 330g / L, a second unit (granule, pill or tablet) of lower density can be produced, and the strength is relatively weak, which causes the second unit to disintegrate faster, and ultimately causes the faster release of the drug, ensuring a release level similar to that of the control drug.

[0062] Preferably, the surface of the first unit of the present invention may be lubricated by mixing with talc.

[0063] Further, preferably, the surface of the second unit of the present invention may be lubricated by mixing with talc.

[0064] Further, preferably, the surface of the second unit of the present invention may be polished and coated with carnauba wax, and the polished and coated surface of the second unit may be lubricated by mixing with talc.

[0065] The lubrication treatment refers to, for example, mixing the first unit or the second unit with talc. For example, the lubrication treatment can be performed by placing the first unit or the second unit in a bin mixer, adding talc, and mixing for 5 minutes.

[0066] The first unit or the second unit subjected to lubrication treatment can be independently made into granules, pellets or tablets, and each unit can have an enteric coating surface, a moisture-proof inner coating and an enteric coating surface, or a moisture-proof inner coating, an enteric coating surface and a polishing coating.

[0067] Preferably, the first unit to be lubricated may be a pill or a tablet, the surface of which is coated with an enteric coating base.

[0068] Further, preferably, the second unit to be lubricated may be a pill or a tablet, the surface of which is coated with a moisture-proof inner coating base, coated with an enteric coating base thereon, and then polished with carnauba wax thereon.

[0069] Preferably, the surface of the first unit of the present invention may be coated with an enteric coating base, and the surface of the enteric-coated first unit may be lubricated by mixing with talc. The surface of the second unit may be coated with a moisture-proof inner coating base, further coated with an enteric coating base thereon, and then polished coated with carnauba wax thereon, and the surface of the polished coated second unit may be lubricated by mixing with talc.

[0070] In the present invention, the ratio of talc used for lubrication treatment of the first unit may be 0.07 to 1.6 wt % with respect to the weight of the first unit.

[0071] When the ratio of talc for lubrication treatment is less than 0.07 wt % relative to the weight of the first unit, the content stability of acetylsalicylic acid is significantly reduced, whereas when the ratio exceeds 1.6 wt %, there is a problem of delayed dissolution.

[0072] In a specific experimental example, dissolution tests were performed on Examples 9 to 11 and Comparative Examples 9 to 11 (which were produced by changing only the talc ratio for lubrication treatment of the first unit). As a result, Comparative Examples 10 and 11 (wherein the talc ratio for lubrication treatment exceeded 1.6% by weight relative to the first unit) showed a dissolution rate of less than 85% at 45 minutes after the start of dissolution, confirming insufficient drug release. On the other hand, Examples 5 to 8 (wherein the talc ratio for lubrication treatment was 0.07 to 1.6% by weight relative to the first unit) showed both acid resistance and sufficient drug release ( Fig.13 and Fig.14 ).

[0073] In addition, in the specific experimental examples, the above-mentioned Comparative Example 9 shows that at the 12th week of the accelerated test, the acetylsalicylic acid content is less than 95%, and the amount of salicylic acid-related substances (RRT 0.70-related substances) exceeds the reference value. On the other hand, Examples 9 to 11 show that during the 12-week accelerated test, the acetylsalicylic acid content is maintained at 95% or more, and almost no salicylic acid-related substances (RRT 0.70-related substances) are generated, indicating good stability ( Fig.15 and Fig.16 ).

[0074] Furthermore, in the present invention, the ratio of talc used for lubrication treatment of the second unit may be 0.05 to 1.2 wt % relative to the weight of the core ordinary tablet of the second unit.

[0075] When the ratio of talc for lubrication treatment is less than 0.05 wt% relative to the weight of the core plain tablet of the second unit, the content stability of rabeprazole is significantly reduced, and when the ratio exceeds 1.2 wt%, there is a problem of delayed dissolution.

[0076] In a specific experimental example, dissolution tests were performed on Examples 5 to 8 and Comparative Examples 5 to 8 (which were produced by changing only the talc ratio for lubrication treatment of the second unit). As a result, Comparative Examples 6 to 8 (wherein the talc ratio for lubrication treatment exceeded 1.2% by weight of the core ordinary tablet of the second unit) showed a dissolution rate of less than 85% at 45 minutes after the start of dissolution, confirming insufficient drug release. At the same time, Examples 5 to 8 (wherein the talc ratio for lubrication treatment was 1.2% by weight or less relative to the core ordinary tablet of the second unit) showed both acid resistance and sufficient drug release ( Figure 8 and Fig. 9 ).

[0077] In addition, in the specific experimental examples, the above-mentioned comparative example 5 shows that at the 12th week of the accelerated test, the content of rabeprazole is less than 95%, and the amount of rabeprazole sulfone related substances (RRT 0.80 related substances) and the total amount of related substances exceed the reference value. At the same time, Examples 5 to 8 show that during the 12-week accelerated test, the content of rabeprazole is maintained at 95% or more, and the amount of rabeprazole RRT 0.80 related substances and the total amount of related substances are low, ensuring good stability ( Figures 10 to 12 ).

[0078] The polishing coating using carnauba wax can be performed by any method known in the art. In the present invention, the polishing coating of the second unit can further improve the fluidity and filling property of the preparation during the formulation process. Specifically, for example, when the first unit and the polished coated second unit are filled into a poly-cap and formulated, the fluidity and filling property of the first unit and the second unit can be improved, and the defect rate can be improved.

[0079] Preferably, the polishing coating of the present invention may be performed by spraying carnauba wax dispersed in a solvent.

[0080] For example, the polishing coating can be performed by putting carnauba wax in a solvent (such as a mixture of water and ethanol), dispersing it in a homogenizer to prepare a polishing coating solution, and then putting the solution in a coater and spraying it to perform the polishing coating.

[0081] In a specific experimental example, the content stability between Example 6 (using a dispersion prepared by dispersing carnauba wax in a liquid) and Comparative Example 12 (spraying the solid as it is when performing polishing coating) was compared in an accelerated test, and the results showed that at the 12th week of the accelerated test, Example 6 had excellent rabeprazole content stability, while Comparative Example 12 had poor rabeprazole content stability ( Figures 17 to 19 ).

[0082] The first unit and the second unit of the present invention may each independently further comprise any one or more pharmaceutically acceptable additives selected from the group consisting of an excipient, a binder, a lubricant, a disintegrant, and a mixture thereof.

[0083] The excipient, binder, lubricant and disintegrant may be any excipient, binder, lubricant and disintegrant known in the art, respectively, and they are not particularly limited as long as the pharmaceutical composition of the present invention does not inhibit the desired effect.

[0084] The pharmaceutical composition of the present invention can be administered once a day.

[0085] The pharmaceutical composition of the present invention can be used in all cases where simultaneous, sequential or combined administration of acetylsalicylic acid and a proton pump inhibitor is required.

[0086] Preferably, the pharmaceutical composition of the present invention can be used for patients at risk of developing gastric or duodenal ulcers, to inhibit thrombosis in myocardial infarction, cerebral infarction or unstable angina, to inhibit thrombosis after coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, or to reduce the cardiovascular risk of high-risk patients.

[0087] More preferably, the pharmaceutical composition of the present invention can be used for patients who are at risk of developing gastric or duodenal ulcers due to daily administration of low-dose aspirin (acetylsalicylic acid) of 100 mg or less, for inhibiting thrombosis in myocardial infarction, cerebral infarction or unstable angina, for inhibiting thrombosis after coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, for reducing cardiovascular risk in high-risk patients, etc.

[0088]

Beneficial effects

[0089] The pharmaceutical composition of the present invention is divided into a first unit and a second unit, which prevents direct contact between drugs, thereby ensuring drug stability and minimizing the influence on individual release, resulting in improved dissolution rate. BRIEF DESCRIPTION OF THE DRAWINGS

[0090] Figure 1 The structure of the poly-cap of the present invention is shown.

[0091] Figure 2 is an image of a poly-cap produced according to Example 3 of the present invention.

[0092] Figure 3 The 0.1N HCl dissolution test results of Examples 1 to 4 of the present invention and Comparative Examples 1 to 4 are shown.

[0093] Figure 4 The pH 6.8 dissolution test results of Examples 1 to 4 of the present invention and Comparative Examples 1 to 4 are shown.

[0094] Figure 5 The accelerated test results obtained by measuring the rabeprazole contents of Examples 1 to 4 of the present invention and Comparative Examples 1 to 4 are shown.

[0095] Figure 6 The accelerated test results obtained by measuring the contents of rabeprazole RRT 0.80-related substances of Examples 1 to 4 of the present invention and Comparative Examples 1 to 4 are shown.

[0096] Figure 7 The accelerated test results obtained by measuring the contents of the total rabeprazole-related substances of Examples 1 to 4 of the present invention and Comparative Examples 1 to 4 are shown.

[0097] Figure 8 The 0.1N HCl dissolution test results of Examples 5 to 8 of the present invention and Comparative Examples 5 to 8 are shown.

[0098] Fig. 9 The pH 6.8 dissolution test results of Examples 5 to 8 of the present invention and Comparative Examples 5 to 8 are shown.

[0099] Fig.10 The accelerated test results obtained by measuring the rabeprazole contents of Examples 5 to 8 of the present invention and Comparative Examples 5 to 8 are shown.

[0100] Fig.11Shown are accelerated test results obtained by measuring the contents of rabeprazole sulfone-related substances (rabeprazole RRT 0.80-related substances) of Examples 5 to 8 of the present invention and Comparative Examples 5 to 8.

[0101] Fig.12 The accelerated test results obtained by measuring the contents of total rabeprazole-related substances of Examples 5 to 8 of the present invention and Comparative Examples 5 to 8 are shown.

[0102] Fig.13 The 0.1N HCl dissolution test results of Example 6 and Examples 9 to 11 of the present invention and Comparative Examples 9 to 11 are shown.

[0103] Fig.14 The pH 6.8 dissolution test results of Example 6 and Examples 9 to 11 of the present invention and Comparative Examples 9 to 11 are shown.

[0104] Fig.15 Accelerated test results obtained by measuring the aspirin (acetylsalicylic acid) contents of Example 6 and Examples 9 to 11 and Comparative Examples 9 to 11 are shown.

[0105] Fig.16 Accelerated test results obtained by measuring the contents of salicylic acid-related substances of Example 6 and Examples 9 to 11 of the present invention and Comparative Examples 9 to 11 are shown.

[0106] Fig.17 The accelerated test results obtained by measuring the rabeprazole contents of Example 6 of the present invention and Comparative Example 12 are shown.

[0107] Fig.18 The accelerated test results obtained by measuring the contents of rabeprazole sulfone-related substances (rabeprazole RRT 0.80-related substances) of Example 6 of the present invention and Comparative Example 12 are shown.

[0108] Fig.19 The accelerated test results obtained by measuring the contents of salicylic acid-related substances of Example 6 of the present invention and Comparative Example 12 are shown. DETAILED DESCRIPTION

[0109] Hereinafter, the present disclosure will be described in more detail through embodiments and experimental examples. These embodiments and experimental examples are provided only for illustrative purposes to help understand the present invention, and the scope of the present invention is not limited by these embodiments.

[0110] Preparation Example 1: Acetylsalicylic acid enteric coated pills

[0111] Acetylsalicylic acid, microcrystalline cellulose and hydroxypropyl cellulose were mixed in a high speed mixer, and then purified water was added, followed by a combination process. Then, extruded pellets were produced using an extruder and a spheronizer.

[0112] The obtained spheronized extruded pellets were enteric coated with a solution of hydroxypropylmethylcellulose phthalate and diethyl phthalate in ethanol and acetone, and finally mixed with magnesium stearate as a lubricant to produce acetylsalicylic acid enteric coated pellets. The specific composition is shown in Table 1 below.

[0113] [Table 1]

[0114]

[0115]

[0116] Preparation Example 2: Acetylsalicylic acid enteric coated tablets

[0117] Acetylsalicylic acid, microcrystalline cellulose, pregelatinized starch and light anhydrous silicic acid were mixed in a silo mixer and screened stearic acid and talc were added for final mixing to prepare a final blend for direct compression. The final blend was compressed to produce tablets.

[0118] The produced tablets were enteric coated with a solution of hydroxypropylmethylcellulose phthalate, diacetylated monoglyceride and titanium dioxide in anhydrous ethanol and acetone at a ratio of 1:2 to produce acetylsalicylic acid enteric coated tablets. The specific composition is shown in Table 2 below.

[0119] [Table 2]

[0120]

[0121] Preparation Example 3: Rabeprazole enteric coated pills

[0122] Rabeprazole sodium, mannitol, magnesium oxide, hydroxypropyl cellulose and low-substituted hydroxypropyl cellulose are mixed in a high-speed mixer, and then anhydrous ethanol is added, followed by a combination process. Then, extruded pellets are produced using an extruder and a spheronizer.

[0123] The obtained spheronized extruded pellets were enteric coated with a solution of hydroxypropylmethylcellulose phthalate and diethyl phthalate in ethanol and acetone, and finally mixed with magnesium stearate as a lubricant to produce rabeprazole enteric coated pellets. The amount of rabeprazole in the pills can be increased to 20 mg, at which point the formula can be increased proportionally. The specific composition is shown in Table 3 below.

[0124] [Table 3]

[0125]

[0126]

[0127] Preparation Example 4: Rabeprazole enteric coated tablets

[0128] Rabeprazole sodium, mannitol, magnesium oxide, hydroxypropyl cellulose and low-substituted hydroxypropyl cellulose are mixed in a high-speed mixer, and then anhydrous ethanol is added, followed by a combination process, drying and crystallization to produce granules. Crosslinked carboxymethyl cellulose sodium as a disintegrant, hydroxypropyl cellulose as a binder, and magnesium stearate as a lubricant are added and finally mixed, and the mixture is tableted to produce tablets.

[0129] The produced tablets were subjected to moisture-proof inner coating using a coating solution containing a mixture of ethyl cellulose and magnesium oxide dissolved in anhydrous ethanol, followed by enteric coating with a solution of hydroxypropyl methylcellulose phthalate, glycerol fatty acid ester, talc, titanium dioxide and yellow iron oxide in a solvent (in which anhydrous ethanol and purified water were mixed in a ratio of 8:2), thereby producing rabeprazole enteric coated tablets. The specific composition is shown in Table 4 below.

[0130] [Table 4]

[0131]

[0132]

[0133] Preparation Example 5: Acetylsalicylic acid enteric-coated pills lubricated with talcum powder

[0134] Acetylsalicylic acid and hydroxypropylcellulose are added to isopropanol and dispersed with a homogenizer to prepare a drug coating solution, which is then sprayed onto the core sugar ball using a coating machine to produce drug coated pills. Use a coating machine to dissolve the drug coated pills produced in pure water with a solution of Eudragit and triethyl citrate. The enteric coated pills produced are put into a silo mixer and lubricated (bin mixing speed: 15rpm) by adding talcum powder and mixing for 5 minutes. The specific composition is shown in Table 5 below.

[0135] [Table 5]

[0136]

[0137] Preparation Example 6: Rabeprazole enteric coated tablets after polishing coating and talc lubrication

[0138] The enteric coated tablets of rabeprazole produced according to the method described in Preparation Example 4 were subjected to carnauba wax polishing coating. The polishing coating solution was prepared by adding carnauba wax to a solvent of water and ethanol and dispersing it with a homogenizer. The specific polishing coating conditions were as follows:

[0139] Homogenizer speed: 200rpm

[0140] Inlet air temperature: Target 55℃

[0141] Outlet temperature: Target 45℃

[0142] Coating machine speed (Pan speed): 5.0rpm

[0143] Air flow meter: Target 120l / min

[0144] Atomizing air pressure: 3.0kgf / cm 2

[0145] The polished coated rabeprazole enteric coated tablets were then placed in a silo mixer and lubricated by adding talc and mixing for 5 minutes (silo mixing speed: 15 rpm).

[0146] Examples 1 to 4: Acetylsalicylic acid and rabeprazole compound preparation (poly-cap)

[0147] According to the method described in the above Preparation Example 4, rabeprazole enteric-coated tablets were produced using the composition (unit: mg) in the following Table 6.

[0148] [Table 6]

[0149]

[0150]

[0151] The produced rabeprazole enteric-coated tablets and the acetylsalicylic acid enteric-coated pellets produced by the method described in the above Preparation Example 1 were filled into one capsule of the poly-cap form to produce composite formulations of Examples 1 to 4.

[0152] Comparative Examples 1 to 4: Acetylsalicylic acid and rabeprazole compound preparation (poly-cap)

[0153] According to the method described in the above Preparation Example 4, rabeprazole enteric-coated tablets were produced using the composition (unit: mg) in the following Table 7.

[0154] [Table 7]

[0155]

[0156]

[0157] The produced rabeprazole enteric-coated tablets and the acetylsalicylic acid enteric-coated pellets produced by the method described in the above Preparation Example 1 were filled into one capsule of the poly-cap form to produce composite formulations of Comparative Examples 1 to 4.

[0158] Experimental Example 1: Dissolution Tests in Examples 1 to 4 and Comparative Examples 1 to 4

[0159] The dissolution of the acetylsalicylic acid and rabeprazole composite formulations produced in Examples 1 to 4 and Comparative Examples 1 to 4 was evaluated. Dissolution was performed under the corresponding conditions to compare the release under acid resistance and high pH. Specifically, based on the single agent control example (Polite tablets 5 mg TM ), and the drug release in 0.1N HCl solution and pH 6.8 solution was compared. The dissolution conditions and analysis conditions are as follows.

[0160] Dissolution solution: 0.1N HCl (900 mL), pH 6.8 buffer (900 mL)

[0161] Dissolution device: Paddle

[0162] Speed: 100rpm

[0163] Temperature: 37℃

[0164] Preparation of test solution: After adding one tablet of the drug to the corresponding dissolution solution, 5 mL of the test solution was taken at 30, 60 and 120 minutes for 0.1N HCl, and 5 mL of the test solution was taken at 5, 10, 15, 30, 45 and 60 minutes for pH 6.8 solution, and then filtered through a 0.45 μm membrane filter with a sampling volume of 1 mL. The solution was mixed with 0.5N NaOH in a ratio of 1:1 to prepare the test solution.

[0165] Preparation of standard solution: Take 50 mg of rabeprazole standard and add it to a 50 mL flask, then dissolve it with the diluent according to the mark. Then, take 1 mL and put it into a 100 mL flask, then dissolve it with the corresponding dissolution solution according to the mark. Mix this solution with 0.5 N NaOH in a ratio of 1:1 to prepare the standard solution.

[0166] Detector: UV-Vis absorption spectrophotometer (measurement wavelength: 290nm)

[0167] Chromatographic column: C18 (4.6mm×150mm, 5μm particle size)

[0168] Column temperature: about 30°C

[0169] Flow rate: Adjust the retention time of rabeprazole sodium to approximately 5 minutes.

[0170] Mobile phase: a mixture of methanol and 0.05 mol / L phosphate buffer (pH 7.0) (3:2, v / v)

[0171] Diluent: a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2, v / v)

[0172] Separately, the dissolution test results under 0.1N HCl are shown in Figure 3 and Table 8, and the dissolution results at pH 6.8 are shown in Figure 4 and Table 9.

[0173] [Table 8]

[0174]

[0175] [Table 9]

[0176]

[0177] Since rabeprazole is not acid-resistant, acid resistance can be considered to be achieved when the dissolution rate is less than 10% when dissolved under acidic conditions for 120 minutes. Figure 3 As shown in Table 8, the composite formulations of Examples 1 to 4 and Comparative Examples 3 and 4 exhibited a dissolution rate of less than 10% at 120 minutes of dissolution, thereby achieving acid resistance; however, the composite formulations of Comparative Examples 1 and 2 having lower enteric coating ratios failed to ensure sufficient acid resistance because they had 18.9% and 13.5%, respectively, at 120 minutes of dissolution, which exceeded 10%. In this case, the amount of rabeprazole degraded in gastric acid may increase, thereby failing to show sufficient drug efficacy. From the above results, it can be confirmed that the enteric coating ratio of rabeprazole should be at least 3% by weight relative to the rabeprazole ordinary tablets to ensure acid resistance.

[0178] At the same time, if Figure 4 As shown in Table 9, considering the absorption site of rabeprazole, the dissolution test at pH 6.8 showed a dissolution rate of 85% or more at 45 minutes, which was similar to the dissolution rate of the control example, indicating that gastrointestinal ulcers were effectively prevented by rapid release. Examples 1 to 4 and Comparative Examples 1 and 2 showed a dissolution rate of 85% or more at 45 minutes of dissolution, while Comparative Examples 3 and 4 having an enteric coating ratio of more than 15% by weight showed a dissolution rate of less than 85% at 45 minutes of dissolution due to a delay in dissolution time.

[0179] The above results confirm that when the enteric coating ratio of the rabeprazole enteric-coated tablets of Examples 1 to 4 is 3 to 15% by weight relative to the rabeprazole plain tablets, both acid resistance and effective drug release can be provided.

[0180] Experimental Example 2: Evaluation of content stability in Examples 1 to 4 and Comparative Examples 1 to 4

[0181] It is known that rabeprazole is unstable at low pH, and when exposed to a humid environment, it changes color to yellow and degrades to sulfone or sulfide-based compounds, thereby changing its crystalline form. Therefore, under accelerated conditions (40° C., 75% RH), for Examples 1 to 4, Comparative Examples 1 to 4 and Control Example (Polit Tablet 5 mg TM ), the change of rabeprazole content, the increasing trend of related substances with a relative retention time ratio of 0.80 to rabeprazole (RRT 0.80 related substances) and total related substances were evaluated. The specific conditions are as follows:

[0182] Preparation of test solutions: 10 of these drugs were accurately weighed and dissolved in a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2) to make exactly 50 mL.

[0183] Preparation of standard solution: Take 50 mg of rabeprazole standard and add it to a 50 mL flask, then dissolve it with diluent according to the mark. Then, take 1 mL and put it into a 100 mL flask, then dissolve it with diluent according to the mark.

[0184] Detector: UV-Vis absorption spectrophotometer (measurement wavelength: 290nm)

[0185] Chromatographic column: C18 (4.6mm×150mm, 5μm particle size)

[0186] Column temperature: about 30°C

[0187] Flow rate: Adjust the retention time of rabeprazole sodium to approximately 5 minutes.

[0188] Mobile phase: a mixture of methanol and 0.05 mol / L phosphate buffer (pH 7.0) (3:2, v / v)

[0189] Diluent: a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2, v / v)

[0190] The results are shown in Figures 5 to 7 middle.

[0191] like Figure 5As shown, Examples 1 to 4, Comparative Examples 3 and 4 and the control showed good stability during the 12-week accelerated test, with a content of 95% or more, while Comparative Examples 1 and 2 showed a content of less than 95% from the 8th week of the accelerated test. It is presumed that this is due to the relatively thin thickness of the enteric coating in Comparative Examples 1 and 2, which allows moisture to penetrate rapidly and causes the moisture-proof inner coating to crack under the thermal conditions of the accelerated test, resulting in moisture infiltration into the core tablet, which causes the degradation of the main components and a decrease in the content.

[0192] In addition, if Figure 6 As shown, during the 12-week accelerated test, the amount of rabeprazole RRT 0.80-related substances in Examples 1 to 4, Comparative Examples 3 to 4 and the Control Example was less than 0.8% of the reference value, but after 4 weeks of the accelerated test, the reference value of 0.8% was exceeded in Comparative Example 1, and after 8 weeks of the accelerated test, the reference value of 0.8% was exceeded in Comparative Example 2.

[0193] In addition, if Figure 7 As shown, during the 12-week accelerated test, in Examples 1 to 4, Comparative Examples 3 to 4 and the Control Example, the total amount of rabeprazole-related substances was less than 2% of the reference value, specifically less than 1.5%, but after 8 weeks of the accelerated test, it exceeded the reference value of 2% in Comparative Example 1, and after 12 weeks of the accelerated test, it was very close to the reference value of 2% in Comparative Example 2.

[0194] These results are presumably caused by the relatively thin enteric coating content (thickness) of Comparative Examples 1 and 2, which resulted in increased moisture permeation and degradation of the main ingredients, as shown in the content stability test.

[0195] Examples 5 to 8: Acetylsalicylic acid and rabeprazole compound preparation (poly-cap)

[0196] The lubricated acetylsalicylic acid enteric-coated pellets produced by the method described in the above Preparation Example 5 and the polished coated and talc-lubricated rabeprazole enteric-coated tablets produced by the method described in the above Preparation Example 6 (having the composition of Table 10 below) were filled into one capsule in the form of poly-cap to produce the composite formulations of Examples 5 to 8 (unit: mg). The ratio of talc lubricant was calculated and expressed as the mass ratio of talc to tablet based on rabeprazole plain tablets (60 mg).

[0197] [Table 10]

[0198]

[0199]

[0200]

[0201] Comparative Examples 5 to 8: Acetylsalicylic acid and rabeprazole compound preparation (poly-cap)

[0202] The lubricated acetylsalicylic acid enteric-coated pellets produced by the method described in the above Preparation Example 5 and the polished coated and talc-lubricated rabeprazole enteric-coated tablets produced by the method described in the above Preparation Example 6 (having the composition of Table 11 below) were filled into one capsule in the form of poly-cap to produce the composite formulations (unit: mg) of Comparative Examples 5 to 8. The ratio of talc lubricant was calculated and expressed as the mass ratio of talc to tablet based on rabeprazole ordinary tablets (60 mg).

[0203] [Table 11]

[0204]

[0205]

[0206] Experimental Example 3: Dissolution Tests in Examples 5 to 8 and Comparative Examples 5 to 8

[0207] The dissolution of the acetylsalicylic acid and rabeprazole compound formulations produced in Examples 5 to 8 and Comparative Examples 5 to 8 was evaluated. Dissolution was performed under the corresponding conditions to compare the acid resistance and the release under high pH. Specifically, the acid resistance in 0.1N HCl solution and the drug release in pH 6.8 solution were compared. The dissolution conditions and analysis conditions are as follows.

[0208] Dissolution solution: 0.1N HCl (900 mL), pH 6.8 buffer (900 mL)

[0209] Dissolution Tester: Paddle

[0210] Speed: 100rpm

[0211] Temperature: 37℃

[0212] Preparation of test solution: After adding one tablet of this drug to the corresponding dissolution solution, 5 mL of the test solution was taken at 30, 60 and 120 minutes for 0.1N HCl and at 5, 10, 15, 30, 45 and 60 minutes for pH 6.8 solution, and then filtered through a 0.45 μm membrane filter with a sampling volume of 1 mL. The solution was mixed with 0.5N NaOH in a ratio of 1:1 to prepare the test solution.

[0213] Preparation of standard solution: Take 50 mg of rabeprazole standard and add it to a 50 mL flask, then dissolve it with the diluent according to the mark. Then, take 1 mL and put it into a 100 mL flask, then dissolve it with the corresponding dissolution solution according to the mark. Mix this solution with 0.5 N NaOH in a ratio of 1:1 to prepare the standard solution.

[0214] Detector: UV-Vis absorption spectrophotometer (measurement wavelength: 290nm)

[0215] Chromatographic column: C18 (4.6mm×150mm, 5μm particle size)

[0216] Column temperature: about 30°C

[0217] Flow rate: Adjust the retention time of rabeprazole sodium to approximately 5 minutes.

[0218] Mobile phase: a mixture of methanol and 0.05 mol / L phosphate buffer (pH 7.0) (3:2, v / v)

[0219] Diluent: a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2, v / v)

[0220] Separately, the dissolution test results under 0.1N HCl are shown in Figure 8 and Table 12, and the dissolution results at pH 6.8 are shown in Fig. 9 and Table 13.

[0221] [Table 12]

[0222]

[0223] [Table 13]

[0224]

[0225] As discussed previously, since rabeprazole is not acid-resistant, acid resistance can be considered to be achieved when the dissolution rate is less than 10% when dissolved under acidic conditions for 120 minutes. Figure 8 As shown in Table 12, the composite formulations of Examples 5 to 8 and Comparative Examples 5 to 8 exhibited a dissolution rate within 10% at 120 minutes of dissolution, thereby achieving acid resistance.

[0226] At the same time, if Fig. 9As shown in Table 13, considering the absorption site of rabeprazole, the dissolution test at pH 6.8 showed a dissolution rate of 85% or more at 45 minutes, indicating that gastrointestinal ulcers are effectively prevented by rapid release. Examples 5 to 8 and Comparative Example 5 (wherein the amount of talc lubricant treatment is 1.2 wt % or less) showed a dissolution rate of 85% or more at 45 minutes of dissolution, while Comparative Examples 6 to 8 (wherein the amount of talc lubricant treatment is greater than 1.2 wt %) showed a dissolution rate of less than 85% at 45 minutes after the start of dissolution, indicating delayed dissolution.

[0227] Experimental Example 4: Evaluation of content stability in Examples 5 to 8 and Comparative Examples 5 to 8

[0228] It is known that rabeprazole is unstable at low pH, and when exposed to a humid environment, it changes color to yellow and degrades into sulfone or sulfide-based compounds, thereby changing its crystalline form. Therefore, under accelerated conditions (40° C., 75% RH), for Examples 5 to 8 and Comparative Examples 5 to 8, the change in rabeprazole content, as well as the increasing trend of rabeprazole sulfone-related substances and total related substances were evaluated. The specific conditions are as follows:

[0229] Preparation of test solutions: 10 of these drugs were accurately weighed and dissolved in a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2) to make exactly 50 mL.

[0230] Preparation of standard solution: Take 50 mg of rabeprazole standard and add it to a 50 mL flask, then dissolve it with diluent according to the mark. Then, take 1 mL and put it into a 100 mL flask, then dissolve it with diluent according to the mark.

[0231] Detector: UV-Vis absorption spectrophotometer (measurement wavelength: 290nm)

[0232] Chromatographic column: C18 (4.6mm×150mm, 5μm particle size)

[0233] Column temperature: about 30°C

[0234] Flow rate: Adjust the retention time of rabeprazole sodium to approximately 5 minutes.

[0235] Mobile phase: a mixture of methanol and 0.05 mol / L phosphate buffer (pH 7.0) (3:2, v / v)

[0236] Diluent: a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2, v / v)

[0237] The results are shown in Figures 10 to 12 middle.

[0238] like Fig.10 As shown, Examples 5 to 8 and Comparative Examples 6 to 8 showed good stability during the 12-week accelerated test, with a content of 95% or greater, while Comparative Example 5 showed that the rabeprazole content decreased rapidly over time, with a content of less than 95% at the 12th week of the accelerated test.

[0239] In addition, if Fig.11 and Fig.12 As shown, Examples 5 to 8 and Comparative Examples 6 to 8 showed that sulfone-related substances (RRT 0.80-related substances) and total related substances were less than 0.8% and less than 2.0%, respectively, during the 12-week accelerated test, but Comparative Example 5 showed that sulfone-related substances (RRT 0.80-related substances) exceeded the reference value of 0.8% after 4 weeks of accelerated testing, and the total related substances far exceeded the reference value of 2.0% after 12 weeks.

[0240] From the above results, it was confirmed that the stability of the rabeprazole preparation was further improved when lubrication treatment was performed.

[0241] Examples 9 to 11: Acetylsalicylic acid and rabeprazole compound preparation (poly-cap)

[0242] In order to compare the effects of different lubrication ratios of acetylsalicylic acid enteric-coated pellets, lubricated acetylsalicylic acid enteric-coated pellets produced by the method described in the above Preparation Example 5 and polished coated and talc-lubricated rabeprazole enteric-coated tablets produced by the method described in the above Preparation Example 6 (having the composition of Table 14 below) were filled into one capsule in the form of poly-cap to produce the composite formulations of Examples 9 to 11 (unit: mg). The ratio of talc lubricant was calculated and expressed as the mass ratio of talc to pellets based on acetylsalicylic acid enteric-coated pellets (132.5 mg).

[0243] [Table 14]

[0244]

[0245]

[0246] Comparative Examples 9 to 11: Acetylsalicylic acid and rabeprazole compound preparation (poly-cap)

[0247] In order to compare the effects of different lubrication ratios of acetylsalicylic acid enteric-coated pellets, lubricated acetylsalicylic acid enteric-coated pellets produced by the method described in the above Preparation Example 5 and polished coated and talc-lubricated rabeprazole enteric-coated tablets (having the composition of Table 15 below) produced by the method described in the above Preparation Example 6 were filled into one capsule in the form of poly-cap to produce composite formulations of Comparative Examples 9 to 11 (unit: mg). The ratio of talc lubricant was calculated and expressed as the mass ratio of talc to pellets based on acetylsalicylic acid enteric-coated pellets (132.5 mg).

[0248] [Table 15]

[0249]

[0250]

[0251] Experimental Example 5: Dissolution Tests in Example 6, Example 9 to Example 11 and Comparative Examples 9 to Comparative Examples 11

[0252] The dissolution of the acetylsalicylic acid and rabeprazole compound formulations produced in Example 6, Example 9 to Example 11 and Comparative Examples 9 to Comparative Examples 11 was evaluated. Dissolution was performed under the corresponding conditions to compare the acid resistance and the release under high pH. Specifically, the acid resistance in 0.1N HCl solution and the drug release in pH 6.8 solution were compared. The dissolution conditions and analysis conditions are as follows.

[0253] Dissolution solution: 0.1N HCl (900 mL), pH 6.8 buffer (900 mL)

[0254] Dissolution Tester: Paddle

[0255] Speed: 100rpm

[0256] Temperature: 37℃

[0257] Preparation of test solution: After adding one tablet of this drug to the corresponding dissolution solution, 5 mL of the test solution was taken at 30, 60 and 120 minutes for 0.1N HCl and at 5, 10, 15, 30, 45 and 60 minutes for pH 6.8 solution, and then filtered through a 0.45 μm membrane filter with a sampling volume of 1 mL. The solution was mixed with 0.5N NaOH at a ratio of 1:9 to prepare the test solution.

[0258] Preparation of standard solution: Take 11.1 mg of aspirin standard and add it to a 100 mL flask, then dissolve it with the dissolution solution according to the marked line. Then, take 5 mL and put it into a 50 mL flask, then dissolve it with the corresponding mobile phase according to the marked line. This liquid is used as the standard solution.

[0259] Detector: UV-Vis absorption spectrophotometer (measurement wavelength: 290nm)

[0260] Chromatographic column: C18 (4.6mm×150mm, 5μm particle size)

[0261] Column temperature: about 40°C

[0262] Flow rate: 1.0mL / min

[0263] Mobile phase: a mixture of 0.3% orthophosphoric acid and acetonitrile (65:35, v / v)

[0264] Analysis time: 10 minutes

[0265] Separately, the dissolution test results under 0.1N HCl are shown in Fig.13 and Table 16, and the dissolution results at pH 6.8 are shown in Fig.14 and Table 17.

[0266] [Table 16]

[0267]

[0268]

[0269] [Table 17]

[0270]

[0271] As discussed previously, since rabeprazole is not acid-resistant, acid resistance can be considered to be achieved when the dissolution rate is less than 10% when dissolved under acidic conditions for 120 minutes. Fig.13 As shown in Table 16, the composite formulations of Example 6, Example 9 to Example 11 and Comparative Examples 9 to Comparative Examples 11 showed a dissolution rate within 10% at 120 minutes of dissolution, thereby achieving acid resistance.

[0272] At the same time, if Fig.14 As shown in Table 17, considering the absorption site of rabeprazole, the dissolution test at pH 6.8 showed a dissolution rate of 85% or more at 45 minutes, indicating that gastrointestinal ulcers can be effectively prevented by rapid release. Example 6, Example 9 to Example 11 and Comparative Example 9 showed a dissolution rate of 85% or more at 45 minutes of dissolution, while Comparative Examples 10 and 11 (in which the amount of talc lubrication treatment was greater than 1.6% by weight) showed a dissolution rate of less than 85% at 45 minutes of dissolution due to a delay in dissolution time.

[0273] From the above results, it was confirmed that when acetylsalicylic acid enteric-coated pellets were lubricated with 0.07 to 1.6 wt %, both acid resistance and good drug release could be achieved.

[0274] Experimental Example 6: Evaluation of content stability in Example 6, Examples 9 to 11 and Comparative Examples 9 to 11

[0275] It is known that rabeprazole is unstable at low pH, and when exposed to a humid environment, it changes color to yellow and degrades into sulfone or sulfide-based compounds, thereby changing its crystalline form. Therefore, under accelerated conditions (40° C., 75% RH), for Example 6, Example 9 to Example 11 and Comparative Examples 9 to Comparative Examples 11, the change in rabeprazole content and the increasing trend of rabeprazole sulfone-related substances and total related substances were evaluated. The specific conditions are as follows:

[0276] Preparation of test solution: Take 20 of these capsules and separate the pellets from the capsules and accurately weigh an amount equivalent to 5 capsules, put it in a 100 mL flask and dissolve it in the diluent in a 100 mL volumetric flask to make the volume exactly 100 mL.

[0277] Preparation of standard solution: Take 20mg and 30mg of aspirin and salicylic acid standards respectively and add them to a 100mL flask, then dissolve them with diluent according to the mark. Then, take 5mL and put it into a 100mL flask, then dissolve it with diluent according to the mark.

[0278] Detector: UV-visible absorption spectrophotometer (measurement wavelength: 280nm)

[0279] Chromatographic column: C18 (3.9mm×300mm, 10μm particle size)

[0280] Column temperature: about 35°C

[0281] Flow rate: 2.0mL / min

[0282] Mobile phase: a mixture of water and acetonitrile (1000 mL, 850:150, v / v), 2 g of sodium 1-heptanesulfonate was added, and the pH was adjusted to 3.4 with acetic acid.

[0283] Diluent: acetonitrile·formic acid (99:1, v / v)

[0284] Analysis time: 60min

[0285] The results are shown in Fig.15 and Fig.16 middle.

[0286] like Fig.15As shown, Examples 6, 9 to 11 and Comparative Examples 10 and 11 showed good stability in the 12-week accelerated test, with a content of 95% or greater, while Comparative Example 9 showed that the acetylsalicylic acid content decreased rapidly over time, with a content of less than 95% in the 12th week of the accelerated test.

[0287] In addition, if Fig.16 As shown, Examples 6, 9 to 11 and Comparative Examples 10 and 11 showed salicylic acid-related substances (RRT 0.80) far less than the reference value of 3.0% during the 12-week accelerated test, but Comparative Example 9 showed that salicylic acid-related substances increased rapidly over time and exceeded the reference value of 3.0% after 12 weeks of accelerated testing.

[0288] It can be seen that when lubrication treatment is not performed as in Comparative Example 9, the accelerated conditions of moisture and heat cause the stability of the acetylsalicylic acid preparation to be significantly reduced.

[0289] Comparative Example 12: Acetylsalicylic acid and rabeprazole compound preparation (poly-cap)

[0290] In order to compare the stability of the preparations according to the polishing coating spraying method, Comparative Example 12 of the composite preparation of acetylsalicylic acid and rabeprazole was produced. Specifically, the lubricated acetylsalicylic acid enteric coated pellets produced by the method described in the above Preparation Example 5 according to the following Table 18 and the polished coated and talc lubricated rabeprazole enteric coated tablets produced by the method described in the above Preparation Example 6 and the polishing coating conditions according to the contents of the following Table 18 (provided that the polishing coating was performed by spraying solid carnauba wax for 5 minutes and then lubricated with talc) were filled into a capsule in the form of a poly-cap to produce the composite preparation of Comparative Example 12 (unit: mg).

[0291] [Table 18]

[0292]

[0293]

[0294] Experimental Example 7: Evaluation of content stability in Comparative Example 12

[0295] In order to compare the effect of the polishing coating method, under accelerated conditions (40°C, 75% RH), the change in rabeprazole content and the increasing trend of rabeprazole sulfone-related substances and total related substances were evaluated for Example 6 and Comparative Example 12. The specific conditions are as follows:

[0296] Preparation of test solutions: 10 of these drugs were accurately weighed and dissolved in a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2) to make exactly 50 mL.

[0297] Preparation of standard solution: Take 50 mg of rabeprazole standard and add it to a 50 mL flask, then dissolve it with diluent according to the mark. Then, take 1 mL and put it into a 100 mL flask, then dissolve it with diluent according to the mark.

[0298] Detector: UV-Vis absorption spectrophotometer (measurement wavelength: 290nm)

[0299] Chromatographic column: C18 (4.6mm×150mm, 5μm particle size)

[0300] Column temperature: about 30°C

[0301] Flow rate: Adjust the retention time of rabeprazole sodium to approximately 5 minutes.

[0302] Mobile phase: a mixture of methanol and 0.05 mol / L phosphate buffer (pH 7.0) (3:2, v / v)

[0303] Diluent: a mixture of methanol and 0.01 mol / L sodium hydroxide reagent solution (3:2, v / v)

[0304] The results are shown in Figures 17 to 19 middle.

[0305] like Fig.17 As shown, Example 6 exhibited good stability in the 12-week accelerated test, with a content of 95% or greater, while Comparative Example 12 showed that the rabeprazole content decreased rapidly over time, with a content of less than 95% at the 12th week of the accelerated test.

[0306] In addition, if Fig.18 and Fig.19 As shown, Example 6 showed that the rabeprazole sulfone-related substances (RRT 0.80-related substances) and salicylic acid-related substances were less than the reference values ​​of 0.8% and 3.0%, respectively, during the 12-week accelerated test, but Comparative Example 12 showed that the rabeprazole sulfone-related substances (RRT 0.80-related substances) exceeded the reference value of 0.8% after 8 weeks of the accelerated test, and the salicylic acid-related substances exceeded the reference value of 3.0% after 12 weeks.

[0307] From the above results, it can be seen that the formulation stability is further improved when the polish coating is performed by spraying the wax dispersed in the solvent as a liquid, rather than directly applying the solid wax.

Claims

1. A pharmaceutical composition comprising: a first unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and The second unit comprises a proton pump inhibitor.

2. The pharmaceutical composition according to claim 1, wherein the acetylsalicylic acid or a pharmaceutically acceptable salt thereof has a dosage of 50 to 150 mg per unit dosage form.

3. The pharmaceutical composition according to claim 1, wherein the proton pump inhibitor is selected from the group consisting of rabeprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, dexlansoprazole, ilaprazole, S-pantoprazole and pharmaceutically acceptable salts thereof.

4. The pharmaceutical composition according to claim 3, wherein the dosage of rabeprazole is 5 to 20 mg per unit dosage form. 5 . The pharmaceutical composition according to claim 1 , wherein the first unit and the second unit are each independently any one or more selected from granules, pills and tablets. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in the form of a capsule or a tablet.

7. The pharmaceutical composition according to claim 1, wherein the first unit is a pill, and the second unit is a pill.

8. The pharmaceutical composition according to claim 1, wherein the first unit is a pill, and the second unit is a tablet.

9. The pharmaceutical composition according to claim 1, wherein the first unit is a tablet and the second unit is a pill.

10. The pharmaceutical composition according to claim 1, wherein the first unit is a tablet, and the second unit is a tablet.

11. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a capsule, and the capsule comprises a first unit and a second unit, and the first unit and the second unit are any one or more selected from granules, pills, and tablets.

12. The pharmaceutical composition according to claim 1, wherein the surface of the first unit is coated with an enteric coating base.

13. The pharmaceutical composition according to claim 1, wherein the surface of the second unit is coated with an enteric coating base.

14. The pharmaceutical composition according to claim 1, wherein the surface of the second unit is coated with a moisture-proof inner coating base, and further coated with an enteric coating base thereon.

15. The pharmaceutical composition according to any one of claims 12 to 14, wherein the enteric coating base is any one or more selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate, shellac, methacrylic acid-ethyl acrylate copolymer (methacrylic acid-ethyl acrylate copolymer), ethyl acrylate-methyl methacrylate copolymer (ethyl acrylate-methyl methacrylate copolymer), acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate trimellitate and sodium carboxymethyl cellulose.

16. The pharmaceutical composition according to any one of claims 12 to 14, wherein the enteric coating base is any one or more selected from the group consisting of hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate, shellac, methacrylic acid-ethyl acrylate copolymer (methacrylic acid-ethyl acrylate copolymer) and ethyl acrylate-methyl methacrylate copolymer (ethyl acrylate-methyl methacrylate copolymer).

17. The pharmaceutical composition according to claim 13 or 14, wherein the content of the enteric coating is 3 to 15% by weight relative to the second unit.

18. The pharmaceutical composition according to claim 14, wherein the moisture barrier inner coating base is any one or more selected from the group consisting of ethyl cellulose, Opadry OY-C-7000A, hydroxypropyl cellulose and hydroxypropyl methyl cellulose.

19. The pharmaceutical composition according to claim 14, wherein the content of the moisture-proof inner coating base is 1 to 3% by weight relative to the second unit.

20. The pharmaceutical composition according to claim 1, wherein the second unit further comprises a basic stabilizer.

21. The pharmaceutical composition according to claim 20, wherein the alkaline stabilizer is any one or more selected from the group consisting of magnesium oxide, magnesium hydroxide, calcium hydroxide, sodium hydroxide, precipitated calcium carbonate and potassium hydroxide.

22. The pharmaceutical composition of claim 21, wherein the bulk density of the magnesium oxide is less than 330 g / L.

23. The pharmaceutical composition according to claim 1, wherein the surface of the first unit is lubricated by mixing with talc.

24. The pharmaceutical composition according to claim 1, wherein the surface of the second unit is lubricated by mixing with talc.

25. The pharmaceutical composition according to claim 1, wherein the surface of the second unit is polished and coated with carnauba wax, and the polished and coated surface of the second unit is lubricated by mixing with talc.

26. The pharmaceutical composition according to claim 1, wherein the surface of the first unit is coated with an enteric coating base, The surface of the enteric-coated first unit is lubricated by mixing with talc, The surface of the second unit is coated with a moisture-proof inner coating base, further coated with an enteric coating base thereon, and then polished with carnauba wax thereon, and The surface of the polished coated second unit was lubricated by mixing with talc.

27. The pharmaceutical composition according to claim 23 or 26, wherein the ratio of talc used for lubricating the first unit relative to the weight of the first unit is 0.07 to 1.6 weight %.

28. The pharmaceutical composition according to any one of claims 24 to 26, wherein the ratio of talc used for lubricating the second unit relative to the weight of the core plain tablet of the second unit is 0.05 to 1.2 wt%.

29. The pharmaceutical composition according to claim 25 or 26, wherein the polish coating is performed by spraying carnauba wax dispersed in a solvent.

30. The pharmaceutical composition according to claim 1, wherein the first unit and the second unit each independently further comprise any one or more pharmaceutically acceptable additives selected from the group consisting of an excipient, a binder, a lubricant, a disintegrant, and a mixture thereof.

31. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is for once-daily administration.

32. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is used for patients at risk of developing gastric or duodenal ulcers, to inhibit thrombosis in myocardial infarction, cerebral infarction or unstable angina; to inhibit thrombosis after coronary artery bypass grafting or percutaneous transluminal coronary angioplasty; or to reduce cardiovascular risk in high-risk patients.

Citation Information

Patent Citations

  • Orally disintegrating tablet

    KR101908748B1

  • Dry coated tablet

    KR101952478B1